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Lyme disease, caused by Borrelia burgdor-
feri and transmitted by ticks, was ini-
tially considered a recent, rare and regional
occurrence. We now have evidence that
very similar bacteria infected humans in
Europe during the ice age (Keller et al.,
2012). Evidence-based data are scarce
therefore many aspects of the disease
remain controversial (Auwaerter et al.,
2011; Lee and Vielmeyer, 2011; Perronne,
2012), but in 2013 the Centers for Disease
Control and Prevention (CDC) revised
their annual estimates from 30,000 cases
to 300,000 cases in the USA alone. Having
dramatically increased their numbers, the
CDC are now calling Lyme disease “a
tremendous public health problem in the
United States” (CDC, 2011).
The lack of a gold standard for diag-
nosis makes producing accurate statistics
difficult. Some pathogenic strains belong-
ing to the B. burgdorferi sensu lato com-
plex have a worldwide distribution, yet
they are rarely considered or tested for
(Varela et al., 2004; Lopes de Carvalho
et al., 2009; Rudenko et al., 2009; Stanek
and Reiter, 2011; Branda and Rosenberg,
2013; Clark et al., 2013; Lee et al., 2014;
Margos et al., 2014). Borrelia miyamo-
toi, for instance, phylogenetically close
to relapsing fever borreliae, is now rec-
ognized as a cause of Lyme-like disease
and relapsing fever in Asia, Europe and
North America. It usually does not cross
react with B. burgdorferi tests (Branda and
Rosenberg, 2013; Lee et al., 2014). A novel
isolate of Borrelia has been isolated by PCR
in a post-treatment serum from a patient
with neurologic Lyme disease (Lee et al.,
2014).
These recent historical, geographical
and microbial data should prompt the
medical community to realize that cases
of persisting post tick-bite syndromes are
probably due to multiple pathogens and
that these occult infections will require a
new approach if not an actual paradigm
shift.
DIAGNOSTIC PITFALLS IN ROUTINE
PRACTICE
Classical forms of Lyme disease are usu-
ally easy to manage, but these medical
conditions with pleomorphic non spe-
cific symptoms may prove confusing to
physicians (Strle and Stanek, 2009). Lyme
disease may mimic chronic inflamma-
tory or degenerative diseases, including
a wide range of auto-immune diseases.
Although practitioners from every med-
ical specialty are likely to have encoun-
tered cases of Lyme disease, they may
have failed to recognize it, no matter how
skilled they are. A major obstacle is that
only 30% of the patients report a his-
tory of tick bite and only 70–80% present
with a primary erythema migrans, the
pathognomonic initial lesion. This lesion
may go unrecognized, or be mistaken
for an “insect bite” or an “allergic rash.”
Mini-erythema migrans are less likely
to be diagnosed. Secondary erythema
migrans are observed in approximately
50% of cases. Bacteriologic and pathologic
analogies have been reported between ter-
tiary neuroborreliosis and tertiary neu-
rosyphilis (Miklossy, 2012). Syphilis, once
well-known as the great imitator, gives us
a good historical model for the concept of
occult infection.
OCCULT INFECTIONS AND THEIR ROLE
IN THE PATHOPHYSIOLOGY OF SOME
DISEASES OF UNCLEAR ETIOLOGY
Charles Nicolle, working at the Institut
Pasteur in Tunis and Nobel prize win-
ner in 1928, showed great interest in the
concept of occult infections (“les infec-
tions inapparentes”) like typhus, syphilis,
and relapsing fever (Borrelia recurrentis)
(Nicolle, 1993). Relapsing fever due to
another species of Borrelia (B. crocidu-
rae) is still a public health concern in
some parts of Africa, and the recently dis-
covered B. miyamotoi may also become
a similar problem in Asia, Europe and
America (Schwan et al., 2012; Branda
and Rosenberg, 2013; Lee et al., 2014).
Peptic ulcer disease is another example
of the hidden link between an occult
infection with another spiral-shaped bac-
terium, Helicobacter pylori, and a chronic
disorder. B. burgdorferi may persist in tis-
sues even after antibiotic treatments, as
animal models have shown (Straubinger
et al., 1997; Straubinger, 2000; Hodzic
et al., 2008; Yrjänäinen et al., 2010; Embers
et al., 2012). In fact dormant persister
cells of bacteria from different genera can
escape the bactericidal effect of antibiotics
and be responsible for latent infections
(Phillips et al., 1998; Hunfeld et al., 2005;
Lewis, 2007; Lee et al., 2014). Clinicians
have no diagnostic tests to check for the
persistence of live borreliae. B. burgdor-
feri, having a complex genetic structure,
is a highly adaptable organism capable of
evading immune response through dif-
ferent processes. It can survive extracel-
lularly and intracellularly (Brorson and
Brorson, 1998; Murgia and Cinco, 2004).
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The complexity of Lyme disease requires
high quality diagnostic methods, yet serol-
ogy is the only diagnostic tool widely used.
SEROLOGY, THE CURRENT MAIN
DIAGNOSTIC METHOD
Physicians should be made aware that,
in the presence of primary erythema
migrans, serology will often be nega-
tive therefore diagnosis should be clinical
(Wormser, 2006). However, many practi-
tioners are still under the misconception
that a positive serology is required for early
stage diagnosis. For later stages of the dis-
ease serology remains the main diagnos-
tic tool. The Infectious Diseases Society
of America (IDSA) and the European
Concerted Action on Lyme Borreliosis
(EUCALB) are recommending a two-
tier testing approach, the first step being
an ELISA using whole sonicate of the
in vitro cultured tick-derived strain B31
of Borrelia burgdorferi (EUCALB, 1997;
Wormser et al., 2006). If positive, confir-
mation by immunoblot testing IgG and
IgM is required. According to these guide-
lines, immunoblot is not to be performed
if the ELISA is negative. However, in 2011,
the CDC modified their case definition
and included single-tier IgG immunoblot
seropositivity as a diagnostic criterion for
Lyme disease (CDC, 2013). But most
practitioners still use the two-tier system
despite the poor sensitivity of ELISA tests,
ranging from 34 to 70.5 (Marangoni et al.,
2005; Aguero-Rosenfeld, 2008; Ang et al.,
2011; Wojciechowska-Koszko et al., 2011).
Calibration of the tests is a crucial issue.
CALIBRATION OF SEROLOGY
When Lyme serology was developed, no
reliable method was available to be used as
a gold standard for comparison. Asmost of
the signs and symptoms are non-specific,
no reliable clinical diagnostic score could
be established. The low yield of culture
and the difficulty involved in using the
technique routinely were another major
obstacle. A pragmatic cut-off level for
the serologic tests had to be determined
arbitrarily on blood donors (EUCALB,
1997; Assous, 2007). In the late seventies,
when Lyme disease was first discovered, it
was understandably thought to be a rare
and regional phenomenon. Therefore, a
low prevalence was set as experts were
afraid the serologies would produce too
many false positive diagnoses (EUCALB,
1997; Assous, 2007). Patients and con-
trol populations are ill-defined with a high
variability in predictive positive and neg-
ative values from one test to another.
Culture of B. burgdorferi or detection of
its genome by polymerase chain reac-
tion (PCR) may occasionally confirm the
clinical diagnosis in seronegative patients,
however none of these methods are sen-
sitive enough to be considered reliable
diagnostic methods, especially in routine
practice (Schutzer et al., 1990; Nields and
Kveton, 1991; Chmielewska-Badora et al.,
2006; Brunner, 2006; Assous, 2007; Holl-
Wieden et al., 2007; Aguero-Rosenfeld,
2008; Dietrich et al., 2008; Wallet et al.,
2008). As a result, many patients suffer-
ing signs and symptoms compatible with
Lyme disease, but whose test is negative,
are falling by the wayside.
CLINICAL AND EPIDEMIOLOGICAL
CONSEQUENCES OF NEGATIVE
SEROLOGY
Modern medical practice expects to rely
on evidence. Most physicians would not
consider diagnosing Lyme disease without
serological proof. Yet the failure to diag-
nose seronegative neuroborreliosis, espe-
cially the acute or severe forms, can have
dire consequences including chronic neu-
rologic sequelae or even death. A review
of the literature shows that a diagnosis of
Lyme neuroborreliosis is often difficult to
prove (Blanc et al., 2007; Bennet et al.,
2008; Tveitnes et al., 2009; Makhani et al.,
2011). The sensitivity of intrathecal anti-
body index (measuring specific antibod-
ies within the cerebro-spinal fluid) ranges
from 55 to 80%. In a Swedish study, anti-
bodies were present in serum of only 23%
of children with neuroborreliosis (Bennet
et al., 2008). Cognitive tests or SPECT
brain imaging may help to provide objec-
tive evidence (Tager et al., 2001; Roche-
Lanquetot et al., 2008; Fallon et al., 2009;
Donta et al., 2012). Pragmatic diagnos-
tic criteria including response to empiric
antibiotic treatment are used to diag-
nose neuroborreliosis (Blanc et al., 2007).
Should this strategy be recommended in
other clinical presentations as well? In fact
some clinicians will not hesitate to clas-
sify as Lyme disease cases, seronegative
patients with a highly compatible clini-
cal picture, provided other diagnoses have
been ruled out. In a major clinical trial
on Lyme disease, 40% of the enrolled
patients were seronegative. These patients
had a history of erythema migrans, neu-
rologic or cardiac symptoms, radiculoneu-
ropathy or arthritis (Klempner et al.,
2001). Clinicians, often unaware of the
difficulties involved in diagnosing Lyme
disease, will fall back on “weak” alterna-
tive diagnoses (“viral,” “idiopathic,” “auto-
immune,” “degenerative,” “inflammatory,”
or “psychosomatic”) (Kennedy, 2013).
New techniques are needed to accurately
assess these patients. This current over-
reliance on inaccurate testing procedures
not only flaws the diagnosis of individ-
ual patients but it also has epidemiologi-
cal consequences especially as new species
and variants continue to be identified on
all continents (Hao et al., 2011; Rudenko
et al., 2011).
POSSIBLE CAUSES OF
SERONEGATIVITY
Several factors leading to seronegativity
have been identified in confirmed cases
of Lyme disease: (i) the arbitrary cut-
off level of tests, (ii) the sequestration of
antibodies in immune complexes, (iii) the
wide variety of species and subspecies of
Borrelia that co-exist in different parts of
the world, and (iv) coinfections with other
pathogens which may be responsible for
some or all of the symptoms or which may
alter the immune response (Schutzer et al.,
1990; Brunner, 2006). The complex B.
burgdorferi sensu lato includes (Table 1): B.
burgdorferi sensu stricto (including genetic
diversity), B. afzelii, B. garinii (several
serotypes) and additional species isolated
in different parts of the world (Rudenko
et al., 2009, 2011; Ogden et al., 2011).
Some of these species have been isolated in
symptomatic patients (Varela et al., 2004;
Lopes de Carvalho et al., 2009; Rudenko
et al., 2009; Stanek and Reiter, 2011;
Branda and Rosenberg, 2013; Clark et al.,
2013; Lee et al., 2014; Margos et al., 2014).
B. spielmanii may cause early skin disease
(Stanek and Reiter, 2011). B. bavariensis,
B. bisettii, B. valaisiana, B. americana, B.
andersonii, B. lonestari and more recently
B. kurtenbachii have been isolated from
patients with Lyme-like diseases (Varela
et al., 2004; Rudenko et al., 2009; Rizzoli
et al., 2011; Stanek and Reiter, 2011; Clark
et al., 2013). The pathogenic role of B.
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Table 1 | Bacteria responsible for Lyme or Lyme-like disease and other Borrelia sp. belonging to the Borrelia burgdorferi sensu lato complex,
and other tick-borne micro-organisms isolated in humans.
Bacteria responsible for Lyme disease belonging to the Borrelia burgdorferi sensu lato complex
Borrelia burgdorferi sensu stricto (including genetic diversity) North America, Europe, North Africa
Borrelia afzelii Europe, Asia
Borrelia garinii (several serotypes) Europe, Asia, North Africa
Borrelia bavariensis (previously B. garinii OspA serotype 4)
Bacteria responsible for Lyme-like disease
Borrelia lonestari North America
Borrelia miyamotoi (also cause of relapsing fever) Europe, Asia, North America
Non-identified spirochete Brazil
Bacteria occasionally isolated in cases of Lyme-like disease
Borrelia spielmanii Borrelia bisettii
Borrelia andersonii Borrelia valaisiana
Borrelia americana Borrelia kurtenbachii
Novel Borrelia sp. close to relapsing fever borreliae (Lee et al., 2014)
Other Borrelia sp., belonging to the Borrelia burgdorferi sensu lato complex with unknown or poorly documented pathogenicity
Borrelia japonica Borrelia turdi
Borrelia sinica Borrelia tanukii
Borrelia lusitaniae (vasculitis?) Borrelia californiensis
Borrelia carolinensis Borrelia yangtze
Borrelia sp. responsible for relapsing fever
Louse-borne relapsing fever
Borrelia recurrentis
Tick-borne relapsing fever
At least 15 Borrelia sp. including
Borrelia crocidurae (Africa)
Borrelia miyamotoi (also cause of Lyme-like disease)
Other human tick-borne infections
PARASITES
Babesia divergens Babesia microti
BACTERIA
Ehrlichia chaffeensis Anaplasma phagocytophilum
Rickettsia sp. Coxiella burnetii
Francisella tularensis Candidatus Neoehrlichia mikurensis
VIRUSES
Several Flaviviridae (including Tick-borne encephalitis virus)
Bunyaviridae (Crimean-Congo hemorrhagic fever)
lusitaniae, isolated in a case of vasculi-
tis, remains to be substantiated (Rudenko
et al., 2009). Despite such diversity in
strains, most of the commercially avail-
able tests still rely on the original 1982
Massachusetts B31 isolate of B. burgdor-
feri. No diagnostic tool is available for
routine detection of B. miyamotoi (Branda
and Rosenberg, 2013; Lee et al., 2014).
Coinfections with other microbes add to
the complexity of these illnesses (Table 1).
Among patients with early Lyme disease in
the USA, 2–12% were found to also have
human granulocytic anaplasmosis, and
2–40% babesiosis (Wormser et al., 2006).
In Brazil, a Lyme-like syndrome, due to the
tick Amblyomma, has been described and
mobile non cultivable spirochetes could be
visualized in patients’ blood using a dark
field microscope (Mantovani et al., 2007).
A new tick-borne bacterial pathogen,
Candidatus Neoehrlichia mikurensis, was
reported in Switzerland (Fehr et al., 2010).
An illustration of the limits of serology is
the Scottish example: the sensitivity of the
immunoblot was improved by using local
Scottish strains of Borrelia (Mavin et al.,
2007, 2009).
CONCLUSION AND PERSPECTIVES
The numerous complexities of Lyme dis-
ease make it an extremely difficult illness
to fully comprehend. It remains a diagnos-
tic challenge even for the best informed
of clinicians. The lack of a gold standard
for diagnosis renders the management of
patients difficult and seriously hinders our
ability to produce accurate statistics, espe-
cially as very similar syndromes could
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be due to other species of Borrelia. In
some patients suffering from syndromes of
unclear origin, following tick bite, other
microbial agents could also be playing a
role. Lyme disease has now entered the
political debate as shown by the amend-
ment (Section 54.1-2963.2) voted in 2013
by the State of Virginia, USA, that compels
physicians to inform their patients that the
“current laboratory testing for Lyme dis-
ease can be problematic.” The fact that
politicians are being called upon to rule on
these matters should prompt scientists to
regain control of the situation. Politicians
should instead become aware of the neces-
sity to fund research and facilitate the
setting up of independent international
working groups. Reliable testing is essen-
tial to investigate the many syndromes of
unclear origin that may mimic many other
medical disorders. Proper fundamental
and clinical research is urgently needed as
it would be the most cost effective way
of ensuring that patients are accurately
diagnosed and that the best therapeutic
strategies are decided upon (Stricker and
Johnson, 2014). Development of new diag-
nostic methods is badly needed. New PCR
methods and new genomic techniques,
such as high throughput sequencing, could
prove promising in identifying the com-
plex mix of microbial agents that are prob-
ably involved (Vayssier-Taussat et al., 2013;
Lee et al., 2014). Next generation sequenc-
ing allowed the identification of various
bacteria from Ixodes ricinus ticks in France:
Anaplasma phagocytophilum, Bartonella
henselae, B. grahamii, Borrelia afzelii,
B. garinii, B. burgdorferi, B. miyamo-
toi, Candidatus Neoerlichia mikurensis,
Ehrlichia canis, Rickettsia canadensis, R.
felis, and R. helvetica (Vayssier-Taussat
et al., 2013). These new techniques should
be applied to human samples. Other
variables, such as genetic, environmen-
tal, or auto-immune factors should also
be studied. The name “Lyme disease”
is too restrictive as it focuses and fuels
the controversy. A new term should be
agreed upon for these syndromes with
possible infectious involvement, often fol-
lowing tick bites. Closer collaboration
between epidemiologists, microbiologists,
immunologists, geneticians, environmen-
tal scientists, veterinarians, entomolo-
gists, and clinicians is needed to identify
the main agents that could be causing
these occult infections and to determine
strain pathogenicity. A new multidirec-
tional approach is crucial in order to
widen the field of research and to move
forward.
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